Bayer AG

BAYN

DE000BAY0017

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 06:04:00 2024-12-03 am EST			5-day change	1st Jan Change
19.49 ^EUR	+1.07%		+3.12%	-42.06%

09:00am	ZBD Pharma Gets China Approval for Antibacterial Injection	MT
Dec. 02	Bayer: to present its radiology products at RSNA	CF

BAYER AG : Goldman Sachs remains Neutral

November 12, 2024 at 06:24 am EST

In his latest research note, analyst James Quigley confirms his recommendation. The broker Goldman Sachs is keeping its Neutral rating. The target price is unchanged at EUR 30.

Latest news about Bayer AG

ZBD Pharma Gets China Approval for Antibacterial Injection	03:00am	MT
Bayer: to present its radiology products at RSNA	Dec. 02	CF
Bayer: expanding its global network of incubators	Nov. 29	CF
BAYER AG : DZ Bank reiterates its Buy rating	Nov. 27	ZD
German consumer sentiment tumbles in December on job cut fears, GfK report shows	Nov. 27	RE
BridgeBio Pharma Obtains FDA Approval of Attruby	Nov. 25	MT
Dhanuka Agritech Limited Announces Strategic Acquisition Agreement with Bayer AG for Acquiring International Rights to the Active Ingredients Iprovalicarb and Triadimenol	Nov. 25	CI
Dhanuka Agritech Limited Announces Strategic Acquisition Agreement with Bayer AG for Acquiring International Rights to the Active Ingredients Iprovalicarb and Triadimenol to Expand its Global Footprint	Nov. 25	CI
Dhanuka Agritech to Acquire Crop Protection Active Ingredients from Germany's Bayer	Nov. 25	MT
Hua Medicine Terminates Commercialization Agreement with Bayer for Type 2 Diabetes Treatment	Nov. 21	MT
US FDA Accepts Bayer's Supplemental Application for Prostate Cancer Drug	Nov. 21	MT
Bayer: new Nubeqa application filed in the USA	Nov. 21	CF
Bayer at its lowest level in more than 20 years - investors run away	Nov. 21	DP
BAYER AG : UBS sticks Neutral	Nov. 21	ZD
Jefferies lowers target for Bayer to 22 euros - 'Hold'	Nov. 20	DP
Berenberg Cuts Bayer's Price Target Amid 'Minimal' Earnings Growth, Legal Troubles	Nov. 20	MT
BAYER AG : Stifel is Neutral	Nov. 20	ZD
BAYER AG : Jefferies reiterates its Neutral rating	Nov. 19	ZD
Trump-induced Pharma fears shouldn't be long-lived	Nov. 19
Cytokinetics, Bayer in Japan Licensing Pact for Aficamten	Nov. 19	DJ
BAYER : Berenberg lowers its target price	Nov. 19	CF
Bayer secures rights to heart drug in multi-million deal	Nov. 19	RE
Cytokinetics, Bayer Partner to Develop, Commercialize Potential Cardiomyopathy Treatment in Japan	Nov. 19	MT
Bayer, Orbia Unit Develop a New Digital Farming Platform	Nov. 19	MT
Bayer: exclusive licensing agreement with Cytokinetics in Japan	Nov. 19	CF

Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows: - agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.; - pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.; - OTC products and nutritional supplements (12.7%); - other (0.5%). Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).

Employees

94,245

Sector

Pharmaceuticals

Calendar

2024-12-03 - Citi Global Healthcare Conference

More about the company